376 related articles for article (PubMed ID: 23362240)
1. Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells.
Beck D; Niessner H; Smalley KS; Flaherty K; Paraiso KH; Busch C; Sinnberg T; Vasseur S; Iovanna JL; Drießen S; Stork B; Wesselborg S; Schaller M; Biedermann T; Bauer J; Lasithiotakis K; Weide B; Eberle J; Schittek B; Schadendorf D; Garbe C; Kulms D; Meier F
Sci Signal; 2013 Jan; 6(260):ra7. PubMed ID: 23362240
[TBL] [Abstract][Full Text] [Related]
2. RIPK1 regulates survival of human melanoma cells upon endoplasmic reticulum stress through autophagy.
Luan Q; Jin L; Jiang CC; Tay KH; Lai F; Liu XY; Liu YL; Guo ST; Li CY; Yan XG; Tseng HY; Zhang XD
Autophagy; 2015; 11(7):975-94. PubMed ID: 26018731
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic activation of MEK/ERK primes melanoma cells for adaptation to endoplasmic reticulum stress.
Croft A; Tay KH; Boyd SC; Guo ST; Jiang CC; Lai F; Tseng HY; Jin L; Rizos H; Hersey P; Zhang XD
J Invest Dermatol; 2014 Feb; 134(2):488-497. PubMed ID: 23921951
[TBL] [Abstract][Full Text] [Related]
4. BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma.
Niessner H; Sinnberg T; Kosnopfel C; Smalley KSM; Beck D; Praetorius C; Mai M; Beissert S; Kulms D; Schaller M; Garbe C; Flaherty KT; Westphal D; Wanke I; Meier F
Clin Cancer Res; 2017 Oct; 23(20):6203-6214. PubMed ID: 28724666
[No Abstract] [Full Text] [Related]
5. BRAF-mutated cells activate GCN2-mediated integrated stress response as a cytoprotective mechanism in response to vemurafenib.
Nagasawa I; Kunimasa K; Tsukahara S; Tomida A
Biochem Biophys Res Commun; 2017 Jan; 482(4):1491-1497. PubMed ID: 27965097
[TBL] [Abstract][Full Text] [Related]
6. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma.
Ma XH; Piao SF; Dey S; McAfee Q; Karakousis G; Villanueva J; Hart LS; Levi S; Hu J; Zhang G; Lazova R; Klump V; Pawelek JM; Xu X; Xu W; Schuchter LM; Davies MA; Herlyn M; Winkler J; Koumenis C; Amaravadi RK
J Clin Invest; 2014 Mar; 124(3):1406-17. PubMed ID: 24569374
[TBL] [Abstract][Full Text] [Related]
7. ACY-1215 accelerates vemurafenib induced cell death of BRAF-mutant melanoma cells via induction of ER stress and inhibition of ERK activation.
Peng U; Wang Z; Pei S; Ou Y; Hu P; Liu W; Song J
Oncol Rep; 2017 Feb; 37(2):1270-1276. PubMed ID: 28035401
[TBL] [Abstract][Full Text] [Related]
8. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
9. 17-Aminogeldanamycin selectively diminishes IRE1α-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAF
Mielczarek-Lewandowska A; Sztiller-Sikorska M; Osrodek M; Czyz M; Hartman ML
Apoptosis; 2019 Aug; 24(7-8):596-611. PubMed ID: 30989459
[TBL] [Abstract][Full Text] [Related]
10. S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib.
Jiao X; Zhang H; Xu X; Yu Y; Zhang H; Zhang J; Ning L; Hao F; Liu X; Niu M; Chen CT; Chen D; Zhang K
Cell Physiol Biochem; 2018; 49(3):1143-1162. PubMed ID: 30196299
[TBL] [Abstract][Full Text] [Related]
11. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.
Søndergaard JN; Nazarian R; Wang Q; Guo D; Hsueh T; Mok S; Sazegar H; MacConaill LE; Barretina JG; Kehoe SM; Attar N; von Euw E; Zuckerman JE; Chmielowski B; Comin-Anduix B; Koya RC; Mischel PS; Lo RS; Ribas A
J Transl Med; 2010 Apr; 8():39. PubMed ID: 20406486
[TBL] [Abstract][Full Text] [Related]
12. Dangerous liaisons: flirtations between oncogenic BRAF and GRP78 in drug-resistant melanomas.
Shenolikar S
J Clin Invest; 2014 Mar; 124(3):973-6. PubMed ID: 24569370
[TBL] [Abstract][Full Text] [Related]
13. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.
Paraiso KH; Haarberg HE; Wood E; Rebecca VW; Chen YA; Xiang Y; Ribas A; Lo RS; Weber JS; Sondak VK; John JK; Sarnaik AA; Koomen JM; Smalley KS
Clin Cancer Res; 2012 May; 18(9):2502-14. PubMed ID: 22351686
[TBL] [Abstract][Full Text] [Related]
14. Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma.
Yadav V; Zhang X; Liu J; Estrem S; Li S; Gong XQ; Buchanan S; Henry JR; Starling JJ; Peng SB
J Biol Chem; 2012 Aug; 287(33):28087-98. PubMed ID: 22730329
[TBL] [Abstract][Full Text] [Related]
15. Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain.
Wagenaar TR; Ma L; Roscoe B; Park SM; Bolon DN; Green MR
Pigment Cell Melanoma Res; 2014 Jan; 27(1):124-33. PubMed ID: 24112705
[TBL] [Abstract][Full Text] [Related]
16. The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas.
Peh J; Fan TM; Wycislo KL; Roth HS; Hergenrother PJ
Mol Cancer Ther; 2016 Aug; 15(8):1859-69. PubMed ID: 27297867
[TBL] [Abstract][Full Text] [Related]
17. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.
Shi H; Kong X; Ribas A; Lo RS
Cancer Res; 2011 Aug; 71(15):5067-74. PubMed ID: 21803746
[TBL] [Abstract][Full Text] [Related]
18. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
19. Mitochondrial oxidative stress is the Achille's heel of melanoma cells resistant to Braf-mutant inhibitor.
Corazao-Rozas P; Guerreschi P; Jendoubi M; André F; Jonneaux A; Scalbert C; Garçon G; Malet-Martino M; Balayssac S; Rocchi S; Savina A; Formstecher P; Mortier L; Kluza J; Marchetti P
Oncotarget; 2013 Nov; 4(11):1986-98. PubMed ID: 24161908
[TBL] [Abstract][Full Text] [Related]
20. BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress.
Roulstone V; Pedersen M; Kyula J; Mansfield D; Khan AA; McEntee G; Wilkinson M; Karapanagiotou E; Coffey M; Marais R; Jebar A; Errington-Mais F; Melcher A; Vile R; Pandha H; McLaughlin M; Harrington KJ
Mol Ther; 2015 May; 23(5):931-942. PubMed ID: 25619724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
